{
  "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
  "docSlug": "a4fc5169399f8913c54f14d18031629c",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 64,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 10,
  "notes": "Includes detailed clinical trial citations in the footer.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/25",
  "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
  "deckJsonHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917.json",
  "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Disease Control at 2 months and median PFS for STS",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8fe196c8-f0ad-40ae-a5d2-9abde9143715",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.25,
        "x": 0.5,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Tumor Shrinkage and median PFS for Colorectal Cancer",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a9c6337f-7637-4215-9bb0-9359542fb19a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.22,
        "x": 0.75,
        "y": 0.15
      },
      "kind": "list",
      "text": "Key takeaways regarding IMX-110 performance in STS and Colorectal Cancer",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc25228b-2fff-47a6-a15c-014bec579d58",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.95,
        "x": 0.03,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Detailed clinical trial references and methodology notes.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "253a8c7b-279a-44e7-99b6-31ab0109da9b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "IMX-110 Clinical Results Demonstrate Potential for Best-in-Class Efficacy & Safety in Soft Tissue Sarcoma (STS), and Encouraging Efficacy in Colorectal Cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f9d94fa2-94ea-4cd9-98ff-534ce68859f8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "evidence-matrix",
      "slug": null,
      "matchId": "8e569483-a9d2-4eb2-a8c0-8db039cff444",
      "evidence": "Comparison of clinical trial data against benchmarks",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 29,
      "from": 24,
      "beatId": "fd3d2933-01c8-4f4e-b2ff-7ac84717f569",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Sizing",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The market opportunities for Immix Biopharma's therapies are discussed.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    },
    {
      "to": 27,
      "from": 23,
      "beatId": "8a2b8975-ade2-4ded-a004-449e34d77602",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Roadmap",
      "beatSlug": null,
      "evidence": "The clinical development plan and upcoming catalysts are outlined.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}